# US 2018/0021281 A1 · Lipid formulations containing bioactive fatty acids and other bioactive agents

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2018/0021281 A1
- Document ID: US20180021281A1
- Status: Published application
- Kind: A1
- Application number: 15/654,040
- Filed: 2017-07-19
- Published: 2018-01-25
- Earliest claimed: 2016-07-20
- Assignees: Sciadonics, Inc.
- Applicants: Sciadonics, Inc.
- Inventors: Alvin Berger
- Web page: https://patentgrep.com/patent/US20180021281A1

## CPC

- A61K 31/202: having three or more double bonds, e.g. linolenic (eicosanoids, e.g. leukotrienes A61K31/557)
- A23D 9/007: characterised by ingredients other than fatty acid triglycerides
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- C11C 3/00: Fats, oils, or fatty acids by chemical modification of fats, oils, or fatty acids obtained therefrom (sulfonated fats or oils C07C309/62; factice C08H; drying oils C09F)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A23D: EDIBLE OILS OR FATS, e.g. MARGARINES, SHORTENINGS OR COOKING OILS (preservation thereof A23B20/00; production, refinement or preservation of animal or vegetable fats or oils C11B, C11C)
- C11C: FATTY ACIDS FROM FATS, OILS OR WAXES; CANDLES; FATS, OILS OR FATTY ACIDS BY CHEMICAL MODIFICATION OF FATS, OILS, OR FATTY ACIDS OBTAINED THEREFROM

## Abstract

Provided herein is technology relating to compositions containing bioactive non-methylene interrupted fatty acids (NMIFAs) in combination with short chain fatty acids, medium chain fatty acids, ketone bodies and/or endocannabinoids and endocannabinoid-related mediators, and particularly, but not exclusively, to compositions and methods related to the production and use of non-methylene interrupted fatty acids such as sciadonic acids, juniperonic acid, pinoleic acid and dihomopinoleic acid in combination with short chain fatty acids, medium chain fatty acids and/or endocannabinoids and endocannabinoid-related mediators.

## Claims

### Claim 1

A formulation comprising at least 1% w/w non-methylene interrupted fatty acids (NMIFAs) and a second bioactive agent selected from the group consisting of at least 5% w/w medium chain fatty acids, at least 5% w/w short chain fatty acids, at least 1% w/w of endocannabinoids or endocannabinoid mediators, and combinations thereof.

### Claim 2 (depends on 1)

The formulation of claim 1, further comprising at least 2% w/w, at least 5% w/w, at least 10% w/w, or at least 20% w/w of said NMIFAs.

### Claim 3 (depends on 1)

The formulation of claim 1, further comprising from 1% to 10% w/w, 1% to 20% w/w, 5% to 10% w/w, 5% to 20% w/w, or 10% to 20% w/w of said NMIFAs.

### Claim 4 (depends on 1)

The formulation of claim 1, wherein said NMIFAs are selected from the group consisting of sciadonic acid, juniperonic acid, pinoleic acid, dihomopinoleic acid, coniferonic acid (5,9,12,15 18:4) and synthetic fatty acids selected from the group consisting of 1, 11, 14, 17 20:4; 2, 11, 14, 17 20:4; 3, 11, 14 17 20:4; 4, 11, 14 17 20:4; 6, 11,14 17 20:4; 7,11,14 17 20:4; 1, 9, 12, 15 18:4; 2, 9, 12, 15 18:4; 3, 9, 12, 15 18:4; 4, 9, 12, 15 18:4, 5, 9, 12, 15 18:4, 1, 11, 14 20:3; 2, 11, 14 20:3; 3, 11, 14 20:3; 4, 11, 14 20:3; 6, 11, 14 20:3; 1, 9, 12 18:3; 2, 9, 12 18:3; 3, 9, 12 18:3; and 4, 9, 12 18:3 fatty acids.

### Claim 5 (depends on 1)

The formulation of claim 1, further comprising at least 10% w/w, 20% w/w, 30% w/w, 40% w/w, or 50% w/w medium chain fatty acids.

### Claim 6 (depends on 5)

The formulation of claim 5, further comprising from 10% to 90% w/w, 10% to 70% w/w, 10% to 50% w/w, 10% to 40% w/w, 20% to 90% w/w, 20% to 70% w/w, 20% to 50% w/w, 20% to 40% w/w, 30% to 90% w/w 30% to 70% w/w, or 30% to 50% w/w medium chain fatty acids.

### Claim 7 (depends on 5)

The formulation of claim 5, wherein said medium chain fatty acids are selected from the group consisting of C6:0 (caproic acid or hexanoic acid), C7:0 (heptanoic acid), C8:0 (caprylic acid or octanoic acid), C9:0 (nonaoic acid), C10:0 (capric acid or decanoic acid), adipic acid (hexanedioic acid), pimelic acid (heptanedioic acid), suberic acid (octanedioic acid), azelaic acid (nonanedioic acid), and sebacic acid (decanedioic acid).

### Claim 8 (depends on 5)

The formulation of claim 5, wherein said medium chain fatty acids are provided as free fatty acids, esters, triglycerides or phospholipids.

### Claim 9 (depends on 1)

The formulation of claim 1, further comprising at least 10% w/w, 20% w/w, 30% w/w, 40% w/w, or 50% w/w short chain fatty acids.

### Claim 10 (depends on 9)

The formulation of claim 9, further comprising from 10% to 90% w/w, 10% to 70% w/w, 10% to 50% w/w, 10% to 40% w/w, 20% to 90% w/w, 20% to 70% w/w, 20% to 50% w/w, 20% to 40% w/w, 30% to 90% w/w 30% to 70% w/w, or 30% to 50% w/w short chain fatty acids.

### Claim 11 (depends on 9)

The formulation of claim 9, wherein said short chain fatty acids are selected from the group consisting of C3:0 (propanoic acid), C4:0 (butanoic acid), and C5:0 (pentanoic acid).

### Claim 12 (depends on 1)

The formulation of claim 1, further comprising at least 10% w/w, 20% w/w, 30% w/w, 40% w/w, or 50% w/w endocannabinoids or endocannabinoid mediators.

### Claim 13 (depends on 12)

The formulation of claim 12, further comprising from 10% to 90% w/w, 10% to 70% w/w, 10% to 50% w/w, 10% to 40% w/w, 20% to 90% w/w, 20% to 70% w/w, 20% to 50% w/w, 20% to 40% w/w, 30% to 90% w/w 30% to 70% w/w, or 30% to 50% w/w endocannabinoids or endocannabinoid mediators.

### Claim 14 (depends on 12)

The formulation of claim 12, wherein said endocannabinoids or endocannabinoid mediators are selected from the group consisting of 2-arachidonoyl-glycerol (2-AG), N-arachidonoyl-ethanolamine (AEA), 2-arachidonoyl-glycerol ether (2-AGE, noladin ether), O-arachidonoyl-ethanolamine (virodhamine), N-arachidoyl-dopamine (NADA), and oleamide (OEA; N-oleoylethanolamine), N-palmitoylethanolamine (PEA), N-eicosapentaenoyl-ethanolamine, N-docosahexaenoyl-ethanolamine, N-linolenoyl-ethanolamine, palmitaldehyde, and monoglycerides having an arachidonic acid, eicosapentaenoic acid, or docosahexaenoic acid at position 1, 2 or 3 on the glycerol backbone and N-sciadonylethanolamine.

### Claim 15 (depends on 1)

The formulation of claim 1, further comprising from 10% to 90% w/w, 10% to 70% w/w, 10% to 50% w/w, 10% to 40% w/w, 20% to 90% w/w, 20% to 70% w/w, 20% to 50% w/w, 20% to 40% w/w, 30% to 90% w/w 30% to 70% w/w, or 30% to 50% w/w ketone body compounds.

### Claim 16 (depends on 15)

The formulation of claim 15, wherein said ketone body compounds are selected from the group consisting of acetoacetate, beta hydroxyl butyrate, β-hydroxypentanoate (BHP), β-ketopentanoate (BKP), 3-sciadonyl-3-hydroxybutyrate, 3-sciadonyl-1,3-butanediol, 1,3 di-sciadonyl-1,3-butanediol, and their salt and ester derivatives, a beta-hydroxybutyrate salt comprising sodium beta-hydroxybutyrate, arginine beta-hydroxybutyrate, potassium beta-hydroxybutyrate, calcium beta-hydroxybutyrate, magnesium beta-hydroxybutyrate, lithium beta-hydroxybutyrate, lysine beta-hydroxybutyrate, histidine beta-hydroxybutyrate, ornithine beta-hydroxybutyrate, creatine beta-hydroxybutyrate, agmatine beta-hydroxybutyrate, or citrulline beta-hydroxybutyrate; a salt mixture further comprising beta-hydroxy butyrate sodium salt, beta-hydroxy butyrate potassium salt, beta-hydroxy butyrate calcium salt, beta-hydroxy butyrate magnesium salt or combination thereof; or a combination of a beta-hydroxybutyrate salt and 1,3-butanediol, beta-hydroxybutyrate salt and ethyl acetoacetate, beta-hydroxybutyrate salt and ethyl beta-hydroxybutyrate, a salt mixture and 1,3-butanediol, a salt mixture and ethyl acetoacetate, or a salt mixture and ethyl beta-hydroxybutyrate; 1,3-butandiol; 1,3-butanediol acetoacetate diester; esters of acetoacetate; and 3-hydroxybutyrate derivatives.

### Claim 17 (depends on 1)

The formulation of claim 1, further comprising an antioxidant not naturally occurring with said NMIFAs and said medium chain fatty acids, short chain fatty acids and endocannabinoids or endocannabinoid mediators.

### Claim 18 (depends on 1)

A method of increasing ketogenesis, decreasing appetite, suppressing appetite, or decreasing food or caloric intake, in a subject in need thereof comprising administering an effective amount of a formulation as defined in claim 1.

### Claim 19 (depends on 1)

A method of treating one or more symptoms of metabolic syndrome, diabetes 2, insulin resistance, blood sugar levels, and obesity in a subject in need thereof comprising administering an effective amount of a formulation as defined in claim 1.
